Patent ID: 11944689
Assignee: SEAGEN INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 2:
3. The Ligand Drug Conjugate compound of claim 2 wherein W is a Glucuronide Unit in which —W—Yy-D and —W-D+ have structures of:, respectively, or a pharmaceutically acceptable salt thereof, or in pharmaceutically acceptable salt form, or, W is a Peptide Cleavable Unit and —Yy-D— and —Yy-D+ have structures of:, respectively, or pharmaceutically acceptable salts thereof, or in pharmaceutically acceptable salt forms,
wherein
J or J′ is an independently selected heteroatom, optionally substituted;
the dotted curve line indicates optional cyclization of Ry or Ry1 to D′;
R45 is —CH2OH or —CO2H;
N(RY)D′ and —N+(Ry1)(Ry2)D′ moieties, with or without cyclization, represent D and D+, respectively, wherein D′ is the remainder of D or D+;
wherein Ry is hydrogen or optionally substituted C1-C6 alkyl in absence of cyclization to D′ or Ry is optionally substituted C1-C6 alkylene when cyclized to D′;
Ry1 is optionally substituted C1-C6 alkyl, in absence of its cyclization within D+, or Ry1 is optionally substituted C1-C6 alkylene when cyclized within D+;
Ry2 is hydrogen or optionally substituted C1-C6 alkyl; and
wherein —O′— as E′ represents the oxygen heteroatom of an O-glycosidic bond cleavable by a glycosidase, wherein cleavage of that bond or the bond between W and J, as indicated by the wavy line adjacent to J, within a Ligand Drug Conjugate compound initiates release of D as a primary or secondary amine-containing tubulysin or auristatin or initiates release of D+ as a tertiary amine-containing tubulysin or auristatin from that Ligand Drug Conjugate compound.